Analyst Ratings For NASDAQ:ABUS – Arbutus Biopharma (NASDAQ:ABUS)
Today, Chardan Capital reiterated its Buy rating on NASDAQ:ABUS – Arbutus Biopharma (NASDAQ:ABUS) with a price target of $8.25.
Some recent analyst ratings include
- 5/7/2018-Chardan Capital Reiterated Rating of Buy.
- 3/19/2018-Wedbush was Downgraded by analysts at Wedbush from a “Outperform ➝ Neutral” rating to a “” rating. They now have a $9.00 ➝ $6.00 price target on the stock.
- 1/5/2018-B. Riley initiated coverage with a Buy ➝ Buy rating.
- 11/7/2017-Leerink Swann Reiterated Rating of Market Perform.
- 10/4/2017-JMP Securities Reiterated Rating of Outperform.
- 6/2/2017-Ladenburg Thalmann initiated coverage with a Buy rating.
- 1/9/2017-Bloom Burton Upgrade from a “Accumulate ➝ Buy” rating to a “” rating.
Recent Insider Trading Activity For NASDAQ:ABUS – Arbutus Biopharma (NASDAQ:ABUS)
NASDAQ:ABUS – Arbutus Biopharma (NASDAQ:ABUS) has insider ownership of 7.60% and institutional ownership of 62.09%.
- On 10/3/2017 Michael J Sofia, Insider, sold 10,000 with an average share price of $8.00 per share and the total transaction amounting to $80,000.00.
- On 8/15/2017 Michael J Sofia, Insider, sold 30,000 with an average share price of $3.70 per share and the total transaction amounting to $111,000.00.
- On 8/24/2015 Richard C Henriques Jr, Director, bought 1,000 with an average share price of $6.95 per share and the total transaction amounting to $6,950.00.
Recent Trading Activity for NASDAQ:ABUS – Arbutus Biopharma (NASDAQ:ABUS)
Shares of NASDAQ:ABUS – Arbutus Biopharma closed the previous trading session at 6.02 up +0.12 2.12% with shares trading hands.